130 related articles for article (PubMed ID: 37772388)
1. Wnt/β‑catenin signaling is a novel therapeutic target for tumor suppressor CYLD‑silenced glioblastoma cells.
Kanemaru A; Ito Y; Yamaoka M; Shirakawa Y; Yonemaru K; Miyake S; Ando M; Ota M; Masuda T; Mukasa A; Li JD; Saito H; Hide T; Jono H
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37772388
[TBL] [Abstract][Full Text] [Related]
2. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA‑1288 promotes cell proliferation of human glioblastoma cells by repressing ubiquitin carboxyl‑terminal hydrolase CYLD expression.
Yin J; Weng C; Ma J; Chen F; Huang Y; Feng M
Mol Med Rep; 2017 Nov; 16(5):6764-6770. PubMed ID: 28901464
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑422a functions as a tumor suppressor in glioma by regulating the Wnt/β‑catenin signaling pathway via RPN2.
Sun J; Chen Z; Xiong J; Wang Q; Tang F; Zhang X; Mo L; Wang C; Fan W; Wang J
Oncol Rep; 2020 Nov; 44(5):2108-2120. PubMed ID: 33000268
[TBL] [Abstract][Full Text] [Related]
5. HPCAL1 promotes glioblastoma proliferation via activation of Wnt/β-catenin signalling pathway.
Zhang D; Liu X; Xu X; Xu J; Yi Z; Shan B; Liu B
J Cell Mol Med; 2019 May; 23(5):3108-3117. PubMed ID: 30843345
[TBL] [Abstract][Full Text] [Related]
6. Regulatory role of miRNAs on Wnt/β-catenin signaling in tumorigenesis of glioblastoma.
Rahmani F; Hashemian P; Tabrizi AT; Ghorbani Z; Ziaeemehr A; Alijannejad S; Ferns GA; Avan A; Shahidsales S
Indian J Cancer; 2023; 60(3):295-302. PubMed ID: 37787188
[TBL] [Abstract][Full Text] [Related]
7. AMOTL2‑knockdown promotes the proliferation, migration and invasion of glioma by regulating β‑catenin nuclear localization.
Chen X; Lu Y; Guo G; Zhang Y; Sun Y; Guo L; Li R; Nan Y; Yang X; Dong J; Jin X; Huang Q
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036399
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
[TBL] [Abstract][Full Text] [Related]
9. IL‑21/IL‑21R inhibit tumor growth and invasion in non‑small cell lung cancer cells via suppressing Wnt/β‑catenin signaling and PD‑L1 expression.
Xue D; Yang P; Wei Q; Li X; Lin L; Lin T
Int J Mol Med; 2019 Nov; 44(5):1697-1706. PubMed ID: 31573051
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA RUSC1‑AS‑N promotes cell proliferation and metastasis through Wnt/β‑catenin signaling in human breast cancer.
Zhou P; Liu P; Zhang J
Mol Med Rep; 2019 Feb; 19(2):861-868. PubMed ID: 30569097
[TBL] [Abstract][Full Text] [Related]
11. miR‑296‑3p promotes the proliferation of glioblastoma cells by targeting ICAT.
Zhou J; Du G; Fu H
Mol Med Rep; 2020 May; 21(5):2151-2161. PubMed ID: 32323769
[TBL] [Abstract][Full Text] [Related]
12. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
13. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
14. LHPP exerts a tumor-inhibiting role in glioblastoma via the downregulation of Akt and Wnt/β-catenin signaling.
Li C; Yang J; Wang W; Li R
J Bioenerg Biomembr; 2021 Feb; 53(1):61-71. PubMed ID: 33394310
[TBL] [Abstract][Full Text] [Related]
15. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Wang Y; Gao G; Wei X; Zhang Y; Yu J
Drug Des Devel Ther; 2023; 17():1357-1369. PubMed ID: 37181827
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway.
Wang J; Xia X; Tao X; Zhao P; Deng C
Bioengineered; 2021 Dec; 12(1):3934-3946. PubMed ID: 34288811
[TBL] [Abstract][Full Text] [Related]
17. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
18. Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade.
Jia WQ; Zhu JW; Yang CY; Ma J; Pu TY; Han GQ; Zou MM; Xu RX
J Cell Mol Med; 2020 Mar; 24(5):2901-2916. PubMed ID: 32000296
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR‑181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF‑κB signaling pathway.
Yang X; Sun Y; Zhang Y; Han S
Int J Mol Med; 2020 Nov; 46(5):1755-1764. PubMed ID: 32901872
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
